Cervical Cancer Vaccines Market Revenue to Worth Over US$ 6 Billion by 2026, Owing to Increasing Prevalence of Cervical Cancer

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Request Sample

According to The Global Cervical Cancer Vaccines Market Report, by Product Type (Cervarix, Gardasil, and Gardasil 9), By Distribution Channel (Hospitals, Clinics, and Government Entities), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), published by Coherent Market Insights, the global cervical cancer vaccines market was valued at US$ 2,595.5 million in 2018, and is projected to exhibit a CAGR of 12.1% over the forecast period (2019 – 2026).

Cervical cancer can be prevented via widespread immunization with the human papilloma virus (HPV) vaccine, which prevents infection from high-risk HPV strains and also offers protection against the low-risk ones, which cause genital warts. For instance, according to the Centers for Disease Control and Prevention (CDC), HPV vaccines can be administered to girls failing in the age group of 11 or 12 years. Moreover, all teens and adolescents falling between the ages of 9 and 14 should receive two doses of HPV vaccination within a gap of six months.

*The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.

Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2931

Increasing prevalence of cervical cancer is expected to propel growth of the global cervical cancer vaccines market over the forecast period. For instance, according to the World Health Organization, in 2018, cervical cancer was the fourth most frequent cancer in women with an estimated 570,000 new cases representing 6.6% of all female cancers. Moreover, development of low cost vaccines is also expected to aid in growth of the market. For instance, ISA Pharmaceuticals B.V. is focused on manufacturing cervical cancer vaccine, ISA104 ( HPV16) and ISA104 ( HPV16) vaccines is under phase II trial of clinical development.

Initiatives to boost HPV vaccination are expected to propel growth of the global cervical cancer vaccines market. For instance, in 2013, 1.5 million girls were vaccinated with Gavi (The vaccines Alliance) support. Moreover, in 2017, Gavi helped 30 countries to conduct HPV vaccine demonstration programs.

To know the latest trends and insights related to cervical cancer vaccines market Press Release, click the link below: https://www.coherentmarketinsights.com/press-release/cervical-cancer-vaccines-market-to-surpass-us-6-billion-by-2026-1761

Among product type, the Gardasil 9 segment is expected to account for a major revenue share in the global cervical cancer vaccines market in 2026. According to The Advisory Committee on Immunization Practices (ACIP) 2016, Gardasil 9 is the only HPV vaccine available in the U.S. and is recommended for vaccinating girls and boys between 11 and 12 years of age, before they become sexually active. Moreover, ACIP recommends an immunization schedule of two doses before the age of 14 and three doses after the age 14.

Key Takeaways

• The global cervical cancer vaccines market is expected to witness a CAGR of 12.1% during the forecast period (2019–2026)
• Increasing prevalence of cervical cancer is expected to propel growth of the global cervical cancer vaccines market over the forecast period
• Major players operating in the global cervical cancer vaccines market include, GlaxoSmithKline PLC and Merck & Co. Inc.

Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2931

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.